Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Glatiramer acetate.

G Comi1, L Moiola

  • 1Head of the Departments of Neurology and Neurophysiology, University Vita-Salute San Raffaele, Milan, Italy.

Neurologia (Barcelona, Spain)
|May 29, 2002
PubMed
Summary
This summary is machine-generated.

Glatiramer acetate effectively treats relapsing-remitting multiple sclerosis (RR-MS) by reducing disease activity and disability. This synthetic polypeptide therapy is well-tolerated and shows potential neuroprotective effects.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Mitoxantrone prior to interferon beta-1b in aggressive relapsing multiple sclerosis: a 3-year randomised trial.

Journal of neurology, neurosurgery, and psychiatry·2011
Same author

Voxelwise assessment of the regional distribution of damage in the brains of patients with multiple sclerosis and fatigue.

AJNR. American journal of neuroradiology·2011
Same author

Thalamic damage predicts the evolution of primary-progressive multiple sclerosis at 5 years.

AJNR. American journal of neuroradiology·2011
Same author

Cortical lesions in children with multiple sclerosis.

Neurology·2011
Same author

Sensorimotor functional connectivity changes in amyotrophic lateral sclerosis.

Cerebral cortex (New York, N.Y. : 1991)·2011
Same author

A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex(®) ), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis.

European journal of neurology·2011
Same journal

[Amyotrophic neuralgia secondary to Vaxzevria (AstraZeneca) COVID-19 vaccine].

Neurologia (Barcelona, Spain)·2024
Same journal

[SARS-CoV-2 infection: Possible underdiagnosis of cerebral venous sinus thrombosis].

Neurologia (Barcelona, Spain)·2024
Same journal

[Bell's palsy following COVID-19 vaccination: A case report].

Neurologia (Barcelona, Spain)·2024
Same journal

[Parsonage-Turner syndrome post-infection by SARS-CoV-2: A case report].

Neurologia (Barcelona, Spain)·2024
Same journal

[Acute transverse myelitis following SARS-CoV-2 infection].

Neurologia (Barcelona, Spain)·2024
Same journal

[Neurological complications in critical patients with COVID-19].

Neurologia (Barcelona, Spain)·2024
See all related articles

Area of Science:

  • Neuroscience
  • Immunology
  • Pharmacology

Background:

  • Multiple Sclerosis (MS) is a chronic autoimmune disease affecting the central nervous system.
  • Relapsing-remitting MS (RR-MS) is the most common form, characterized by distinct attacks and remissions.
  • Glatiramer acetate (GA) is an established immunomodulatory therapy for RR-MS.

Purpose of the Study:

  • To evaluate the efficacy and safety of Glatiramer Acetate (GA) in treating relapsing-remitting multiple sclerosis (RR-MS).
  • To explore the mechanisms of action and potential neuroprotective effects of GA.

Main Methods:

  • Review of clinical trial data and in vitro/in vivo animal studies.
  • Analysis of Magnetic Resonance Imaging (MRI) to assess lesion activity and disease progression.

Related Experiment Videos

  • Investigation of GA's impact on T cell populations and immune responses.

    • Main Results:

    • GA significantly reduces relapse rates and disability accumulation in RR-MS patients.
    • MRI studies confirm GA's effectiveness in decreasing the number and volume of active brain lesions.
    • GA is generally well-tolerated with a favorable safety profile, showing no teratogenic or mutagenic effects.

    Conclusions:

    • Glatiramer acetate is a safe and effective treatment option for RR-MS.
    • GA's mechanism involves inducing antigen-specific suppressor T cells, leading to reduced inflammation.
    • GA offers a valuable alternative to interferon beta for managing RR-MS, with potential for neuroprotection.